Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine

BACKGROUND: Although several epigenetic drugs have been reported to have therapeutic efficacy for some hematologic neoplasms (HNs) in clinical trials, few achieved disease-free survival benefit. The traditional drug discovery pathway is costly and time-consuming, and thus, more effective strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Bing-Heng, Lin, Wei-Zhi, Chiang, Yu-Ting, Chen, Yeu-Chin, Chung, Chi-Hsiang, Chien, Wu-Chien, Shiau, Chia-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848747/
https://www.ncbi.nlm.nih.gov/pubmed/35186746
http://dx.doi.org/10.3389/fonc.2022.809014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848747/
https://www.ncbi.nlm.nih.gov/pubmed/35186746
http://dx.doi.org/10.3389/fonc.2022.809014

Ejemplares similares